Friday, October 17, 2014 11:11:36 AM
Office Science Press office
Science Press Association
What is the current situation in West Africa?
When will a vaccine be available?
As well Germany is prepared to the epidemic? A joint event of the WPK - science journalists with the German Society for Infectious Diseases (DGI) eV, the German Society for Tropical Medicine and International Health (DTG) eV and eV German Centre for Infection Research (DZIF) and the Robert Koch Institute (RKI)
The Ebola virus is spreading in West Africa still unbraked. So far, at least 9,000 people have been infected with dangerous pathogens, 4,500 of them have died. The actual numbers are probably much higher. The World Health Organization WHO expected in December 5000 to 10,000 new cases -. Weekly
The situation in the countries concerned is devastating. There is a lack there of everything. Terminally ill people need to be sent home, where they bring their family and friends in danger, because there are no free beds in the treatment centers. August Stich from the Medical Mission Hospital in Würzburg, the situation is represented. Matthias grade was for "Doctors Without Borders" in Liberia. He tells us about his experience on the ground. until now - under the pressure of current events - the search is driven by a vehement vaccine. In recent weeks, the clinical examination of the two most advanced candidates has begun. Further studies begin soon - even in Germany. Marylyn Addo from the German Centre for Infection Research (DZIF) at the University Hospital Hamburg-Eppendorf is involved in the studies. It will tell us, among other things the current state of studies and explain which represent the most promising vaccine candidates. Klaus Cichutek by the Paul Ehrlich Institute will report on the possibilities of an accelerated approval process. Currently, the epidemic rages almost exclusively in West Africa. But what if more and more Ebola cases arrive in Central Europe? How well Germany is prepared for a possible spread? And how many patients can be treated in isolation German? Stefan Schmiedel from the University Hospital Hamburg-Eppendorf, Timo Wolf, attending senior physician at the University Hospital of Frankfurt, and Thomas Grünewald, medical director of the Clinic for Infectious Diseases and Tropical Medicine at Leipzig's St. Georg Hospital, talk about their recent experience with Ebola patients and explain current treatment options . The head of the health department in Frankfurt, René Gottschalk and the president of the Robert Koch Institute, Reinhard Burger provide insights which measures taken by the German health care services. program (for further details see p. Annex) 11 Clock welcome Prof. Dr. Gerd Fätkenheuer, University Hospital of Cologne and German Society for Infectious Diseases 11:05 - 12 Clock Podium 1 - Ebola in Africa / state of vaccine development , Dr. Matthias degrees, Quake Brück, "Doctors Without Borders" Prof. Dr August Stich, Medical Mission Hospital, Würzburg , Prof. Dr. Marylyn Addo, German Centre for Infection Research, Hamburg Prof. Dr. Klaus Cichutek, Paul-Ehrlich-Institute, Langen clock 12 - 13 clock Podium 2 - Preparing for Ebola in Germany Dr. Timo Wolf, University Hospital Frankfurt am Main Dr. Thomas Grünewald, Dept. of. Infectious Diseases and Tropical Medicine, Klinikum St. Georg, Leipzig Dr. Stefan Schmiedel, Bernhard-Nocht-Klinik, Hamburg Prof. Dr. René Gottschalk, health department Frankfurt am Main Prof. Dr. Reinhard Burger Robert Koch Institute, Berlin Chair: Kai copper Schmidt, WPK, a journalist for the Süddeutsche Zeitung & Science Venue: health department Frankfurt, Breite Gasse 28, 60313 Frankfurt am Main application: For better preparation, we would ask you to log in: wpk@wpk.org Specify if you want please also short an interview with one of the speakers.
http://idw-online.de/pages/de/news608794
Recent CTSO News
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/11/2023 09:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:25 PM
- CytoSorbents Reports Third Quarter 2023 Financial and Operational Results • GlobeNewswire Inc. • 11/09/2023 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:54 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM